A defensible comparison of point-of-care coagulation analyzers starts with the assay, not the instrument. Procurement teams should separate devices intended for vitamin K antagonist monitoring, heparin management, or hemostasis evaluation and then assess each candidate against the performance characteristics that matter for that use. The Clinical and Laboratory Standards Institute guideline POCT14 provides consensus recommendations for establishing and assessing traditional coagulation assays performed at the point of care, including prothrombin time/international normalized ratio, activated partial thromboplastin time, activated clotting time, and heparin concentration [1][2]. Because the guideline explicitly covers accuracy, precision, clinical safety, and effectiveness, it gives evaluators a documented frame of reference rather than a generic feature list [2]. What follows is a procedural basis for comparing analyzers when the decision must be tied to evidence.
Define the Assay Before the Analyzer
The first procurement decision point is which coagulation assay the organization needs at the point of care. CLSI POCT14 covers prothrombin time/international normalized ratio for vitamin K antagonist therapy, activated partial thromboplastin time and activated clotting time for heparin monitoring, and heparin concentration [1]. The same guideline notes that viscoelastic tests, including thromboelastometry and thromboelastography, and point-of-care platelet function tests are outside its scope [2]. An evaluator comparing a cartridge-based INR device with a viscoelastic system is therefore comparing tools built for different clinical questions.
Setting also constrains the comparison. Near-patient testing is most relevant in intensive care units, emergency departments, operating rooms, and outpatient clinics, where immediate diagnostic information can expedite treatment decisions and influence therapy compliance [1]. A heparin-management analyzer used in cardiac surgery may face different throughput and operator constraints than an INR meter used in an anticoagulation clinic. Documenting the intended setting first prevents evaluators from rewarding features that have no bearing on the clinical workflow.
Separate Manufacturer Claims from Published Validation
A procurement file should distinguish what a manufacturer states from what independent or published studies have measured. For example, a 2025 Scientific Reports study describes Perosphere Technologies' point-of-care coagulometer as a handheld, battery-operated instrument that uses disposable microfluidic cuvettes and detects clotting time through transmitted near-infrared light, with no chemical or biological reagents in the test strip [6]. The authors report that the coagulometer detected apixaban, rivaroxaban, edoxaban, dabigatran, and enoxaparin with high sensitivity and precision, but they also state that further clinical and laboratory studies are underway to confirm results in patients taking a direct oral anticoagulant [6].
For INR devices, the 2024 Mayo Clinic Proceedings validation compared two point-of-care instruments and reported a greater percentage of concordant management decisions between one point-of-care method and the laboratory INR method, relative to the other device [3]. The abstract indicates that difference reflected lower bias for one instrument compared with the other, but the full methods are not available in the retrieved material. Procurement teams should request the complete study before treating that finding as decisive, since concordance depends on the clinical decision thresholds applied [3].
A Worked Selection Exercise for an Anticoagulation Clinic
Suppose a hospital anticoagulation service must compare two candidate INR meters. The team would first list the relevant criteria from CLSI POCT14: accuracy and precision compared with a reference method, agreement within the therapeutic INR range, and the clinical decision concordance produced by each device [1][2]. The team would then request published validation data for each candidate and record, for example, that the Mayo Clinic Proceedings study compared CoaguChek and Coag-Sense PT2 and reported greater concordance with laboratory INR for one of the two [3].
The team would next check the limits of each validation. The bSens.INR study found 98.5% of results met predefined accuracy criteria but reported reduced accuracy above INR 3.7 [7]. That finding matters for a clinic managing high-intensity anticoagulation. A device with strong performance inside the common therapeutic range may still require a laboratory confirmation rule at higher INRs. The evaluation should therefore specify the INR range over which standalone point-of-care use would be accepted and when venous confirmation would be required.
Use Assay-Specific Criteria for Accuracy and Precision
POCT14 offers separate performance recommendations for prothrombin time/international normalized ratio, activated partial thromboplastin time, activated clotting time, and heparin concentration [2]. The guideline describes how to assess accuracy and precision of traditional coagulation assays and how to assess clinical safety and effectiveness [2]. Investigational validations should therefore be read against the specific acceptance criteria for the assay under review, rather than a single universal standard. A device that performs acceptably for INR may not meet the requirements for activated clotting time in high-dose heparin management.
One recent clinical validation, published in Practical Laboratory Medicine in 2026, illustrates how assay-specific limits operate. The authors reported that 98.5% of bSens.INR results met predefined accuracy acceptance criteria compared with a laboratory reference method, and that all duplicate measurements met repeatability criteria with variability below 10% [7]. They also observed that accuracy decreased at INR values above 3.7 and that exploratory analysis identified potential interfering factors warranting further investigation without establishing causal relationships [7]. Such limits should appear in an evaluation matrix, not be averaged away.
Map Analytical Scope and Interferences Explicitly
CLSI POCT14 makes clear that potential assay interferences, including direct oral anticoagulants, are only briefly discussed, and that monitoring direct thrombin inhibitors receives minimal reference [2]. A procurement team evaluating analyzers for a population taking direct oral anticoagulants cannot assume that every point-of-care coagulation device responds meaningfully to every drug class. The 2025 coagulometer study acknowledged that other bedside assays, such as activated clotting time or various viscoelastic assays, did not have discriminatory sensitivity at the low end of direct oral anticoagulant concentration [5].
Precision reporting also requires careful reading. In the 2025 study, percent coefficient of variation values for the coagulometer and manual whole blood clotting time were below 10%, with most below 5%, which the authors described as acceptable precision [5]. That statement is tied to a specific spiked-sample study design across eight volunteers, not to routine clinical use. Procurement documentation should record the matrix, sample type, concentration range, and predicate method for each precision claim so that comparisons are not made between unlike experiments [5][6].
Choose Evidence Anchors for a Worked Comparison
A practical comparison can be structured around three documented evidence anchors. For INR monitoring, the Mayo Clinic Proceedings validation compared two named devices, CoaguChek and Coag-Sense PT2, against laboratory INR and examined concordance of management decisions [3]. For broad anticoagulant detection, the Perosphere Technologies coagulometer study compared the device with manual whole blood clotting time and reported detection of four direct oral anticoagulants plus enoxaparin [5][6]. For heparin and vitamin K antagonist monitoring requirements, POCT14 supplies the performance framework that neither vendor validation replaces [1][2].
These anchors do not produce a cross-device winner. The Mayo study compared two INR meters, while the Scientific Reports study evaluated a different technology class against a legacy whole-blood method. A defensible procurement conclusion would be that an INR-focused clinic should prioritize agreement with laboratory INR and management-decision concordance, whereas a hospital seeking rapid information on direct oral anticoagulant exposure would need to weigh the emerging coagulometer data against its stated need for further clinical confirmation [6][7].
Sources & references
- POCT14Ed2 | Point-of-Care Coagulation Testing and Anticoagulation Monitoring, 2nd Edition · clsi.org
- POCT14 | Point-of-Care Coagulation Testing and Anticoagulation Monitoring · clsi.org
- CoaguChek and Coag-Sense PT2 Meter Point of Care INR Device Validation - Mayo Clinic Proceedings · www.mayoclinicproceedings.org
- Point-of-Care Diagnostics in Coagulation Management - PMC · pmc.ncbi.nlm.nih.gov
- Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants | Scientific Reports · www.nature.com
- Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants | Scientific Reports · www.nature.com
- From laboratory to point of care: Clinical performance and validation of bSens.INR for prothrombin time and INR monitoring · pmc.ncbi.nlm.nih.gov